Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 81 Breast Neoplasms 10 Triple Negative Breast Neoplasms 4 Neoplasm Metastasis 4 Bulbo-Spinal Atrophy, X-Linked 4 Neoplasms 3 Salivary Gland Neoplasms 2 Osteoporosis 2 Thrombocytosis 1 Stage I Prostate Adenocarcinoma AJCC v7 1 Stage I Prostate Adenocarcinoma 1 Sexual Dysfunction, Physiological 1 Recurrence 1 Prostate Adenocarcinoma 1 Primary Myelofibrosis 1 Primary Dysautonomias 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycystic Ovary Syndrome 1 Pancreatic Neoplasms 1 Paget Disease, Extramammary 1 PSA Level Greater Than Two 1 Ovarian Neoplasms 1 Non-Muscle Invasive Bladder Urothelial Carcinoma 1 Non-Muscle Invasive Bladder Neoplasms 1 Non Castrate Metastatic Prostate Cancer 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Metabolic Diseases 1

Interventions

pembrolizumab 37 Gemcitabine 29 Nivolumab 20 Cisplatin 19 atezolizumab 15 avelumab 14 Docetaxel 13 enfortumab vedotin 10 Carboplatin 10 durvalumab 9 Magnetic Resonance Spectroscopy 9 Ipilimumab 8 Paclitaxel 7 Pemetrexed 6 toripalimab 5 cabozantinib 5 Fluorodeoxyglucose F18 5 sacituzumab govitecan 4 cabazitaxel 4 Taxes 4 vinflunine 3 tremelimumab 3 pemigatinib 3 X-Rays 3 Standard of Care 3 Specimen Handling 3 Radiotherapy 3 Mitomycin 3 Immunotherapy 3 Immunoglobulin G 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinoma, Transitional Cell × bicalutamide × Clear all

NCT06018116 2024-02-15

CANUCK-01

CHU de Quebec-Universite Laval

Phase 2 Withdrawn

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡